ABSTRACT
Clozapine is an atypical antipsychotic medication prescribed for the treatment of psychosis associated with resistant schizophrenia. After incorporation in stearylamine-based SLN, this drug was successfully carried into the brain on intravenous and intraduodenal administration (Manjunath and Venkateswarlu 2005). In particular, stearylaminecontaining clozapine SLN were found to give significantly higher plasma levels and AUC as compared to clozapine-loaded SLN without stearylamine and clozapine suspension. Furthermore, biodistribution studies indicated that the administration of stearylamine-containing clozapine SLN resulted in significantly higher amount of clozapine in brain as compared to that of clozapine-loaded SLN without stearylamine and clozapine suspension.
